C-Reactive Protein Testing Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The C-Reactive Protein Testing Market Report is Segmented by Assay Type (Enzyme-Linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA), and More), Detection Range (High-Sensitivity CRP and Conventional CRP), Application (Diabetes, Rheumatoid Arthritis, and More), End User (Hospitals & Clinics, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

C-reactive Protein Testing Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of C-reactive Protein Testing Market with other markets in Healthcare Industry

C-reactive Protein Testing Market Analysis by Mordor Intelligence

The C-Reactive Protein testing market reached USD 3.26 billion in 2025 and is forecast to reach USD 3.69 billion by 2030, expanding at a 2.52% CAGR. This steady growth stems from the pivot toward precision diagnostics, where high-sensitivity assays, multi-analyte inflammation panels and point-of-care formats command pricing power. Heightened regulatory scrutiny—such as the 2025 CLIA acceptance limits that tightened analytical tolerances—favors premium platforms able to deliver trace-level accuracy. In parallel, reimbursement caps that limit repeat testing in the United States are steering laboratories toward value-based utilization models, accelerating adoption of decision-support software bundled with assays. Across mature and emerging markets alike, rapid decentralization of testing to primary care clinics, pharmacies and home-monitoring programs is redefining competitive boundaries within the C-Reactive Protein testing market.

Key Report Takeaways

  • By assay type, Enzyme-Linked Immunosorbent Assay led with 45.35% of C-Reactive Protein testing market share in 2024, while the Lateral-Flow Immunoassay segment is projected to advance at a 7.25% CAGR to 2030.
  • By detection range, high-sensitivity CRP platforms accounted for 60.53% share of the C-Reactive Protein testing market size in 2024 and are forecast to expand at a 6.85% CAGR through 2030.
  • By application, cardiovascular disease dominated with 35.62% revenue share in 2024; sepsis and acute infection testing is the fastest-growing application at a 7.52% CAGR.
  • By end user, hospitals and clinics held 41.82% of 2024 revenues, whereas point-of-care settings are set to grow at an 8.61% CAGR.
  • By geography, North America commanded 38.82% of global revenues in 2024; Asia-Pacific is expected to post the highest regional CAGR of 7.21% through 2030.

Segment Analysis

By Assay Type: Rapid Lateral-Flow Tests Narrow ELISA Lead

Enzyme-Linked Immunosorbent Assay held 45.35% of 2024 revenues thanks to entrenched analyzers and standardized protocols across integrated delivery networks. However, lateral-flow innovation lifted this segment’s 7.25% CAGR, compressing ELISA’s dominance. DNA nanotechnology tripled detection sensitivity, narrowing the accuracy gap with centralized methods and unlocking pharmacy-based testing lanes. Chemiluminescence instruments preserve relevance in high-throughput core labs where 200-sample racks and auto-reagent loading reduce labor costs. Looking ahead, ELISA bench-tops will focus on bundled multi-analyte menus and connectivity hooks, while rapid cassette suppliers court decentralized buyers. The bifurcation underscores how the C-Reactive Protein testing market rewards both high-volume lab integration and ultrafast near-patient convenience, with few middle-ground options remaining.

Growing patient preference for instant answers continues to pull testing outside hospital walls. Lateral-flow suppliers now bundle digital readers that sync to electronic health records, delivering traceable quantitative values rather than subjective color bands. In rural Southeast Asia, government immunization clinics adopted disposable cassettes to guide antibiotic stewardship without waiting days for reference-lab confirmation. Meanwhile, ELISA vendors defend share by embedding reflex-testing algorithms that auto-trigger cytokine panels when CRP surpasses 3 mg/L, positioning central labs as one-stop inflammation hubs. This dual-track evolution highlights why the C-Reactive Protein testing market remains one of diagnostics’ most technology-diverse arenas.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Detection Range: Premium High-Sensitivity Platforms Capture Value

High-sensitivity reagents captured 60.53% of 2024 revenue and are pacing a 6.85% CAGR as clinicians value sub-1 mg/L precision for preventive cardiology. Regulatory bodies mandate tighter proficiency thresholds, pushing vendors to standardize calibrators traceable to IFCC reference material. Conventional range tests still anchor acute-care workflows, diagnosing pneumonia or appendicitis where CRP exceeds 50 mg/L. Yet reimbursement differentials increasingly incentivize labs to report hsCRP for borderline cardiovascular cases, reinforcing premiumization. Suppliers therefore redesign photometric optics and reagent chemistries to hold coefficient-of-variation below 3% at 0.5 mg/L, justifying higher prices.

Muted growth in conventional assays stems from antibiotic stewardship programs that limit unnecessary bacterial screens. Still, emerging markets rely on low-cost conventional kits to meet basic clinical needs. Dual-range analyzers capable of switching analytical modes offer a hedge, letting laboratories consolidate purchasing. These dynamics keep both tiers relevant, but margin expansion clusters around high-sensitivity innovations, demonstrating how detection-range segmentation shapes competitive advantage in the C-Reactive Protein testing market.

By Application: Sepsis Use-Cases Outpace Cardiovascular Mainstay

Cardiovascular disease remained the top revenue generator at 35.62% in 2024, buoyed by entrenched guideline recommendations. Sepsis testing, however, logged a 7.52% CAGR and is eroding share from slower cardiac growth. Emergency departments adopt 15-minute CRP panels alongside lactate and procalcitonin to triage suspected sepsis, accelerating antibiotic initiation when levels exceed 100 mg/L. Rheumatology, inflammatory bowel disease and oncology deploy serial CRP monitoring to track biologic response, producing predictable, subscription-like volumes.

Expansion of sepsis testing stems from heightened awareness of antimicrobial resistance. Hospitals integrate CRP algorithms that override empirical antibiotic orders when levels stay below 20 mg/L at admission, reducing broad-spectrum use. Vendors seize this opportunity by co-marketing CRP cartridges with stewardship software, adding value beyond raw biomarker output. Such application-specific platforms illustrate how participants in the C-Reactive Protein testing industry translate clinical pain points into differentiated product offerings.

Market Share
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By End User: Point-of-Care Channels Lead Growth Curve

Hospitals and clinics retained 41.82% revenue leadership in 2024, but the 8.61% CAGR in point-of-care settings signals a structural shift toward decentralized diagnostics. Community pharmacies, urgent-care centers and telehealth hubs embrace handheld analyzers that combine CRP, HbA1c and lipid profiles, monetizing quick health-checks. Home-care adoption remains nascent, yet connected devices embedding CRP chips position chronic-care management programs for subscription consumables. Reference labs counter with automated high-throughput systems that batch 1,000 samples nightly, enhancing cost per result to defend high-volume contracts.

Growth catalysts in near-patient segments include simplified CLIA-waived workflows and rising patient self-advocacy. As consumers track vitals via wearables, on-demand CRP complements holistic health dashboards. Vendors designing smartphone-paired cartridges capture this behavioral shift, embedding QR-coded calibrations to maintain traceability. Consequently, the C-Reactive Protein testing market size attached to decentralized channels will continue outpacing hospital budgets through 2030.

Geography Analysis

North America’s 38.82% revenue share in 2024 stems from insurer reimbursement clarity and clinician familiarity with hsCRP. Medicare’s three-test lifetime cap reduces routine repeat ordering, nudging labs to focus on first-time precision and digital decision support. Consolidation among service providers—such as Quest Diagnostics’ LifeLabs takeover—intensifies purchasing power, steering analyzer contracts toward end-to-end automation suites. Canadian provinces are integrating hsCRP into cardiovascular screening for individuals aged 45-75, anchoring baseline volumes across public labs.

Asia-Pacific delivers the fastest 7.21% CAGR, fueled by primary-care modernization and infectious-disease applications. China’s CRP-based tuberculosis triage among HIV-positive populations achieved 72.23% sensitivity and 77.66% specificity, showcasing locally tailored use-cases. Vietnam’s pharmacy pilots trimmed antibiotic misuse, bolstering government support for wider CRP rollout. Japan’s healthy-aging policies subsidize hsCRP for adults in metabolic screening programs, wid¬ening the addressable base. Regional suppliers leverage domestic manufacturing incentives to lower unit costs, penetrating rural clinics previously priced out of branded assays, which expands the C-Reactive Protein testing market footprint.

Europe maintains stable demand through rigorous standardization. IFCC’s laboratory medicine guideline initiatives harmonize calibrators across member states, shrinking inter-lab variability and raising clinician confidence. National Health Services in the United Kingdom added CRP to primary-care respiratory infection bundles, reimbursing tests that support antibiotic stewardship. Emerging regions in Middle East & Africa and South America collectively add single-digit share but post double-digit growth where mHealth programs piggyback CRP on multiparameter diagnostic vans servicing remote areas. Each geography thus maps distinctly onto the evolving C-Reactive Protein testing market, creating localized opportunities for agile players.

Growth Rate
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

Moderate consolidation characterizes the field, with top five vendors controlling significant revenue in 2024. Siemens Healthineers differentiates through an automated seven-marker inflammation panel offering results in 35-65 minutes, bundling CRP with cytokines IL-1β, IL-8 and TNFα for richer profiling. Roche posted 8% diagnostics growth in 2024 after launching 21 assays augmented by machine-learning analytics that predict disease flare-ups 48 hours earlier than single-threshold methods. Abbott fortifies its near-patient franchise with the Afinion CRP module that integrates into multi-assay primary-care workstations.

Strategic activity centers on connectivity and menu breadth rather than price cuts. Vendors embed HL7/FHIR interoperability to auto-populate electronic health records, reducing manual entry errors. Some firms pilot subscription models where analyzer placement is free but consumable cartridges carry per-test fees, mirroring printer-ink economics. White-space entrants focus on nanoparticle sensors and home-monitoring platforms, aiming to leapfrog incumbents tied to central-lab workflows. Regulatory pathways favor established players’ quality-system track records, yet nimble startups attract venture funding for disruptive at-home formats that could capture incremental C-Reactive Protein testing market share.

Future competition will hinge on ecosystem positioning: platforms that anchor broader inflammation panels stand to cross-sell cytokine, ferritin and D-dimer assays, deepening account stickiness. Conversely, pure-play CRP devices risk commoditization unless they pivot toward differentiated clinical decision support or niche applications such as pediatrics or obstetrics. The competitive chessboard is thus defined by bundled value propositions rather than isolated analyte performance.

C-reactive Protein Testing Industry Leaders

  1. Abbott Laboratories

  2. F. Hoffmann-La Roche AG

  3. Danaher Corp (Beckman Coulter)

  4. Siemens Healthineers

  5. Thermo Fisher Scientific Inc

  6. *Disclaimer: Major Players sorted in no particular order
C-reactive Protein Testing Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • January 2025: Roche introduced the Elecsys PRO-C3 test for liver fibrosis assessment in metabolic dysfunction-associated steatotic liver disease, returning results in 18 minutes.
  • August 2024: Quest Diagnostics completed the USD 1.0 billion acquisition of LifeLabs, expanding diagnostic coverage across North America.
  • May 2024: Siemens Healthineers launched its automated seven-test inflammation panel integrating CRP and six cytokines for 35-65-minute turnaround.

Table of Contents for C-reactive Protein Testing Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Chronic Disease & Inflammatory-Disorder Burden Accelerates CRP Testing Adoption
    • 4.2.2 High-Sensitivity CRP Endorsed In Major CVD-Risk Guidelines
    • 4.2.3 Rising Incidence Of Endometriosis And Women's Health Screening Programs
    • 4.2.4 Surge In Point-Of-Care (POC) Testing Roll-Outs At Primary-Care Settings
    • 4.2.5 Integration Of CRP Sensors Into Connected Home-Diagnostic Platforms
    • 4.2.6 Nanoparticle-Enhanced Ultrafast ELISA Microfluidic Chips Reach Commercialization
  • 4.3 Market Restraints
    • 4.3.1 Poor Public & Physician Awareness Outside Cardiology
    • 4.3.2 Competing Multi-Analyte Inflammatory Panels With Superior Accuracy
    • 4.3.3 Inter-Platform Analytical Variability Limits Longitudinal Tracking
    • 4.3.4 Medicare Lifetime Three-Test Cap Curbs U.S. Repeat-Testing Volumes
  • 4.4 Porter's Five Forces
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitutes
    • 4.4.5 Intensity of Competitive Rivalry

5. Market Size & Growth Forecasts (Value, USD)

  • 5.1 By Assay Type
    • 5.1.1 Enzyme-Linked Immunosorbent Assay (ELISA)
    • 5.1.2 Chemiluminescence Immunoassay (CLIA)
    • 5.1.3 Immunoturbidimetric Assay
    • 5.1.4 Lateral-Flow Immunoassay
    • 5.1.5 Other Assay Types
  • 5.2 By Detection Range
    • 5.2.1 High-Sensitivity CRP
    • 5.2.2 Conventional CRP
  • 5.3 By Application
    • 5.3.1 Cardiovascular Disease
    • 5.3.2 Rheumatoid Arthritis
    • 5.3.3 Diabetes
    • 5.3.4 Inflammatory Bowel Disease
    • 5.3.5 Cancer
    • 5.3.6 Sepsis & Acute Infection
    • 5.3.7 Other Applications
  • 5.4 By End User
    • 5.4.1 Hospitals & Clinics
    • 5.4.2 Reference & Central Laboratories
    • 5.4.3 Point-of-Care Settings
    • 5.4.4 Academic & Research Institutes
    • 5.4.5 Home-Care Settings
  • 5.5 Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.3.1 Abbott Laboratories
    • 6.3.2 Danaher Corp (Beckman Coulter)
    • 6.3.3 F. Hoffmann-La Roche AG
    • 6.3.4 Siemens Healthineers
    • 6.3.5 Thermo Fisher Scientific
    • 6.3.6 Quest Diagnostics
    • 6.3.7 Randox Laboratories
    • 6.3.8 Getein Biotech
    • 6.3.9 HORIBA Ltd
    • 6.3.10 Boditech Med
    • 6.3.11 Aidian Oy
    • 6.3.12 QuidelOrtho
    • 6.3.13 Sekisui Diagnostics
    • 6.3.14 Becton Dickinson (BD)
    • 6.3.15 Bio-Rad Laboratories
    • 6.3.16 DiaSorin SpA
    • 6.3.17 Shenzhen Mindray Bio-Medical
    • 6.3.18 LumiraDx
    • 6.3.19 ERBA Diagnostics
    • 6.3.20 Wako Pure Chemical (ELITech)

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-Need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global C-reactive Protein Testing Market Report Scope

As per the scope of the report, C-reactive protein (CRP) is one of the highly useful markers of inflammation in the body, which is produced by cells in the liver. C-reactive protein tests are blood tests that measure C-reactive protein levels. These proteins are produced by the liver, and their levels increase when there is inflammation in the body. These tests help to identify and keep track of diseases that cause inflammation, such as certain types of cancer, cardiovascular diseases, and arthritis, among others. The C-reactive protein testing market is segmented by Assay Type (Enzyme-linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA), Immunoturbidimetric Assay, and Other Assay Types), Application (Diabetes, Rheumatoid Arthritis, Cardiovascular Disease, Inflammatory Bowel Disease, Cancer and Other Applications) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Assay Type Enzyme-Linked Immunosorbent Assay (ELISA)
Chemiluminescence Immunoassay (CLIA)
Immunoturbidimetric Assay
Lateral-Flow Immunoassay
Other Assay Types
By Detection Range High-Sensitivity CRP
Conventional CRP
By Application Cardiovascular Disease
Rheumatoid Arthritis
Diabetes
Inflammatory Bowel Disease
Cancer
Sepsis & Acute Infection
Other Applications
By End User Hospitals & Clinics
Reference & Central Laboratories
Point-of-Care Settings
Academic & Research Institutes
Home-Care Settings
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
By Assay Type
Enzyme-Linked Immunosorbent Assay (ELISA)
Chemiluminescence Immunoassay (CLIA)
Immunoturbidimetric Assay
Lateral-Flow Immunoassay
Other Assay Types
By Detection Range
High-Sensitivity CRP
Conventional CRP
By Application
Cardiovascular Disease
Rheumatoid Arthritis
Diabetes
Inflammatory Bowel Disease
Cancer
Sepsis & Acute Infection
Other Applications
By End User
Hospitals & Clinics
Reference & Central Laboratories
Point-of-Care Settings
Academic & Research Institutes
Home-Care Settings
Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current size of the C-Reactive Protein testing market?

The market generated USD 3.26 billion in revenue in 2025 and is projected to reach USD 3.69 billion by 2030.

Which segment is growing fastest within the C-Reactive Protein testing market?

Point-of-care settings lead growth with an 8.61% CAGR, driven by rapid tests deployed in pharmacies and primary-care clinics.

Why are high-sensitivity CRP assays gaining traction?

HsCRP offers sub-1 mg/L precision, now recommended in cardiovascular guidelines and supported by reimbursement, enabling earlier risk detection.

How will regulatory changes in the United States affect test volumes?

Medicare limits hsCRP to three lifetime tests, steering labs toward value-based utilization and favoring platforms delivering richer decision support.

Which region offers the greatest growth opportunity?

Asia-Pacific, expanding at a 7.21% CAGR, benefits from healthcare modernization, point-of-care adoption and infectious-disease applications.

C-reactive Protein Testing Market Report Snapshots